Protalix BioTherapeutics, Inc.
PLX · AMEX
Analyst ratings
strong_buy · 1 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| March 19, 2026 | HC Wainwright & Co. | Reiterates | Buy | $12.00 |
| November 21, 2025 | HC Wainwright & Co. | Maintains | Buy | $12.00 |
Pipeline viability of PRX-115 for uncontrolled gout treatment
PRX-115, Protalix's recombinant PEGylated uricase, demonstrates strong pre-clinical attributes including long half-life, reduced immunogenic risk, and high specific activity. The Phase II study evaluating its efficacy and safety over 24 weeks signals meaningful clinical advancement and positions PRX-115 as a potentially differentiated therapy in the growing gout treatment market.
Despite promising pre-clinical data, PRX-115 remains in early-stage development, with Phase I still ongoing for gout. The lengthy and costly path from Phase I to regulatory approval, combined with Protalix's limited resources as a micro-cap company, raises serious concerns about whether the program can be fully funded and successfully executed.
Financial health and earnings sustainability amid projected EPS decline
Protalix delivered a remarkable 153.85% year-over-year EPS increase on a non-GAAP basis, reaching $0.07. Analysts also forecast 12.02% revenue growth for the next year, and the company carries zero debt-to-equity ratio, suggesting a relatively clean balance sheet that could support continued operational progress.
Despite recent EPS improvement, analysts project a -15.83% EPS decline for the coming year, signaling that profitability gains may not be sustainable. With only an average score on financial health and profitability metrics, and a ChartMill Fundamental rating of just 4 out of 10, the company's financial footing remains fragile.
Stock technical positioning and near-term price trajectory
A buy signal was issued from a pivot bottom on June 23, 2025, with the stock rising 11.85% since then. The long-term Moving Average confirms a general buy signal, and a positive MACD reading over the 3-month period further supports the case for a potential upside recovery from current levels near $1.51.
The stock lies in the middle of a wide and falling short-term trend, with technical models projecting a -37.14% decline over the next three months, potentially bringing the price as low as $0.575. Low liquidity periods amplify this risk, and the ChartMill Technical rating of just 1 out of 10 reinforces a deeply unfavorable near-term outlook.